A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

Grants and Contracts Details

StatusFinished
Effective start/end date1/14/198/31/21

Funding

  • Medpace Inc: $18,614.00